Last Updated: September 23, 2026

Viiv Hlthcare Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for VIIV HLTHCARE

VIIV HLTHCARE has twenty-six approved drugs.

There are seventeen US patents protecting VIIV HLTHCARE drugs.

Summary for Viiv Hlthcare

US Patents:	17
Tradenames:	19
Ingredients:	17
NDAs:	26

Drugs and US Patents for Viiv Hlthcare

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-001	Jan 21, 2021		RX	Yes	No	10,927,129	⤷ Start Trial	Y	Y		⤷ Start Trial
Viiv Hlthcare	SELZENTRY	maraviroc	TABLET;ORAL	022128-002	Aug 6, 2007	AB	RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Viiv Hlthcare	CABENUVA KIT	cabotegravir; rilpivirine	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	212888-001	Jan 21, 2021		RX	Yes	No	11,389,448	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Viiv Hlthcare

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017	7,067,522	⤷ Start Trial
Viiv Hlthcare	JULUCA	dolutegravir sodium; rilpivirine hydrochloride	TABLET;ORAL	210192-001	Nov 21, 2017	6,838,464	⤷ Start Trial
Viiv Hlthcare	EPZICOM	abacavir sulfate; lamivudine	TABLET;ORAL	021652-001	Aug 2, 2004	6,180,639	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for VIIV HLTHCARE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	300 mg/150 mg/300 mg	➤ Subscribe	2011-03-22
➤ Subscribe	Oral Solution	10 mg/mL	➤ Subscribe	2011-11-22
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2009-01-28
➤ Subscribe	Tablets	700 mg	➤ Subscribe	2012-01-18
➤ Subscribe	Tablets	600 mg/300 mg	➤ Subscribe	2007-09-27
➤ Subscribe	Tablets	600 mg/50 mg/300 mg	➤ Subscribe	2017-08-14
➤ Subscribe	Tablets	150 mg and 300 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Tablets	150 mg and 300 mg	➤ Subscribe	2011-08-08
➤ Subscribe	Oral Solution	20 mg/ml	➤ Subscribe	2012-12-27
➤ Subscribe	Tablets	150 mg/300 mg	➤ Subscribe	2007-06-26
➤ Subscribe	Tablets	10 mg, 25 mg and 50 mg	➤ Subscribe	2017-08-14

International Patents for Viiv Hlthcare Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Russian Federation	2643062	⤷ Start Trial
Croatia	P20201241	⤷ Start Trial
South Korea	20110094336	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Viiv Hlthcare Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0933372	08C0015	France	⤷ Start Trial	PRODUCT NAME: FOSAMPRENAVIR CALCIQUE; REG. NO/DATE: EU/1/07/282/001-002 20040712
2924034	SPC/GB19/024	United Kingdom	⤷ Start Trial	PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH LAMIVUDINE AND TENOFOVIR DISOPROXIL; REGISTERED: UK EU/1/18/1333/001-002 20181122; UK PLGB 5305/0015 20181122
2932970	1890039-9	Sweden	⤷ Start Trial	PRODUCT NAME: DOLUTEGRAVIR SODIUM + RILPIVIRINE HYDROCHLORIDE; REG. NO/DATE: EU/1/18/1282 20180518
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Viiv Hlthcare

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.